Mr. Rob Fia reports

THERMA BRIGHT PORTFOLIO UPDATE: INRETIO SUCCESSFULLY COMPLETES FIRST-IN-HUMAN COHORT FOR PREVA(TM) STROKE PLATFORM; TARGETS 2026 U.S. FDA TRIAL

Therma Bright Inc.'s portfolio company, Inretio, has hit a major clinical milestone. The medical device innovator has successfully completed the first cohort of the first-in-human (FIH) study for the PREVA neuro-thrombectomy system, moving the company rapidly toward a planned United States pivotal trial.

Clinical and regulatory acceleration: Following the positive review from the Data Safety Monitoring Board (DSMB), Inretio has received approval to continue patient enrolment. These clinical data are vital for the company's upcoming submission to the United States Food and Drug Administration (FDA). Inretio aims to secure an investigational device exemption (IDE) to launch a multicentre U.S. study later this year, designed to conclude within 24 months.

"We are executing with precision across all critical fronts," said Raviv Vine, chief executive officer of Inretio. "The positive DSMB feedback validates our safety profile and provides a strong foundation for our U.S. strategy. As we prepare for our FDA submission, we are simultaneously refining the PREVA system based on direct physician feedback to ensure superior clinical utility."

Operational scaling and R&D (research and development): Inretio is actively upgrading its manufacturing capabilities to meet pivotal trial demand. This includes expanding facilities and integrating manufacturing enhancements.

Strategic outlook

To fuel these milestones, Inretio is currently advancing a capital raise. These funds will support the U.S. regulatory process, clinical operations and the scaling of manufacturing. The company continues to strengthen relationships with global key opinion leaders (KOLs) and major hospital networks.

"We are thrilled by Inretio's rapid progress and the definitive steps taken toward commercialization," stated Rob Fia, chief executive officer of Therma Bright. "According to the CDC, Ischemic stroke accounts for approximately 87 per cent of all strokes, affecting nearly eight million people globally every year. With the aging population driving incidence rates higher, the market demand for Inretio's intuitive, effective solution is undeniable. We look forward to a transformative 2026."

About Inretio

Inretio is a privately held medical device company based in the Sha'ar HaNegev Industrial Park, Israel. The company is dedicated to transforming acute ischemic stroke care through its PREVA platform, a unique neuro-thrombectomy solution designed to improve the efficacy, speed and accessibility of clot removal procedures.

About Therma Bright Inc.

Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The company's portfolio includes innovative solutions for vascular health, respiratory diagnostics and topical treatments. Therma Bright is listed on the TSX Venture Exchange (THRM), the OTCQB (TBRIF) and the Frankfurt Stock Exchange (JNX0).

We seek Safe Harbor.